Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genome-wide screening reveals the key genes that are responsible for trametinib-induced apoptosis

ABSTRACT: To explore the geness that are responsible for trametinib-induced apoptosis, we performed Genome-scale CRISPR-Cas9 knockout screening in GSU with 0.015% DMSO or 15 nM trametinib for 14 days. We found that TP53 is critical for executing trametinib-induced apoptosis.

ORGANISM(S): Homo sapiens

PROVIDER: GSE152846 | GEO | 2023/06/19

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type

Project description:Recent preclinical studies suggest that combining MEK and MDM2 inhibition synergize to induce apoptosis in RAS/BRAF-mutant and TP53 wild-type CRC models. In vitro, in RKO cell lines (poorly differentiated colon carcinoma cell line resistant to single agent targeting MDM2 and MEK and BRAF inhibition), the MDM2 plus MEK inhibitor combination generated a synergistic increase in apoptotic index. In vivo, in mice harboring human RKO colon tumor xenografts the combination of MDM2 plus MEK inhibition elicited 93% decreases in tumor volume. This trial is to conduct a single-center, Phase 1 dose escalation study of trametinib combined with HDM201 (a HDM2 inhibitor) in patients with advanced/metastatic RAS/RAF mutant and TP53 wt CRC.

| 2287507 | ecrin-mdr-crc

Differentially expressed genes in iKRAS cell treated with Trametinib, 2DG and Combo

Project description:To identify the differentially expressed gene in ikras cells treated with Trametinib, 2DG and Trametinib/2DG combination. Two ikras cells were used for transcriptomics analysis by RNAseq.

2021-06-07 | GSE176242 | GEO

Response and resistance of low grade ovarian cancer cells to trametinib

Project description:HOC-7 and MPSC1 are low grade serous ovarian cancer cell lines. These cells was treated with different doses of trametinib in an attempt to identify biomarkers that can be used to predict chemoresponse to this drug. We used microarrays to identify genes induced by trametinib.

2020-04-15 | GSE148648 | GEO

Transcriptomic analysis of T84 colon carcinoma cell line treated with trametinib, JQ1 or their combination

Project description:T84 cells were treated with DMSO, 30nM trametinib (MEKi), 1µM JQ1 (BRD4i) or the combination of trametinib and JQ1 (combo) for 24h.

2018-10-23 | GSE118548 | GEO

Transcriptomic profile of trametinib on LPS-mediated gene expression in murine peritoneal macrophages

Project description:To determine the underlying mechanisms by which trametinib affected LPS-induced inflammatory response in macrophages, we performed microarrays to define the global gene expression in murine peritoneal macrophages treating with trametinib or vehicle followed by LPS stimulation.

2021-07-12 | GSE134486 | GEO

Transcriptomic analysis of trametinib-resistant HCT116 colorectal carcinoma cells compared to the parental control cells

Project description:HCT116 cells were treated with with increasing concentrations of trametinib over 2 months. Drug-resistant clones emerged and were cultured in the presence of 30 nmol/L trametinib. These cells exhibited a greater than 10-fold increase in the GI50 for trametinib compared to the parental cell line. RNA-seq of the resistant clone HCT116_R4 versus the parental cells identified differentially expressed genes potentially involved in resistance.

2018-10-23 | GSE118490 | GEO

Efficacy of trametinib and dabrafenib associated with radioactive iodine for the treatment of refractory metastatic differentiated thyroid cancer

Project description:Efficacy of a selective MEK (trametinib) and BRAFV600E (dabrafenib) inhibitors associated with radioactive iodine (RAI) for the treatment of refractory metastatic differentiated thyroid cancer with RAS or BRAFV600E mutation. To evaluate the objective response rate according to RECIST criteria in thyroid cancer patients with metastatic radioactive iodine (RAI) refractory disease, 6 months after a treatment combining in each arm of the phase II trial (patients with RAS mutation or patients with BRAFV600E mutation): - Arm A: 6 weeks of trametinib followed by RAI treatment (5.5 GBq following rhTSH) in patients with RAS mutation - Arm B: 6 weeks of trametinib plus dabrafenib followed by RAI treatment (5.5 GBq following rhTSH) in patients with BRAFV600E mutation

2023-09-01 | E-MTAB-12837 | biostudies-arrayexpress

Differentially expressed genes in iKRAS tumor treated with Trametinib or Kras extinction

Project description:To identify the differentially expressed gene in ikras tumors treated with Trametinib or Kras extinction.

2021-06-07 | GSE176241 | GEO

Efficacy of trametinib and dabrafenib associated with radioactive iodine for the treatment of refractory metastatic differentiated thyroid cancer (KRAS cohort)

Project description:Efficacy of a selective MEK (trametinib) and BRAFV600E (dabrafenib) inhibitors associated with radioactive iodine (RAI) for the treatment of refractory metastatic differentiated thyroid cancer with RAS (current cohort) or BRAFV600E mutation. To evaluate the objective response rate according to RECIST criteria in thyroid cancer patients with metastatic radioactive iodine (RAI) refractory disease, 6 months after a treatment combining in each arm of the phase II trial (patients with RAS mutation or patients with BRAFV600E mutation): - Arm A: 6 weeks of trametinib followed by RAI treatment (5.5 GBq following rhTSH) in patients with RAS mutation - Arm B: 6 weeks of trametinib plus dabrafenib followed by RAI treatment (5.5 GBq following rhTSH) in patients with BRAFV600E mutation

2023-09-01 | E-MTAB-12900 | biostudies-arrayexpress

Genome wide CRISPR screen for Trametinib sensitivity in resistant MOLM13 cells using Y. Kosuke library

Project description:Cas9-expressing trametinib resistant MOLM-13 cell lines (TM1) were generated using the Cas9-Blst (Addgene, #52962) and expanded for genome-wide loss-of-function screens using the Y. Kosuke library (Addgene, #67989) Following transduction, cells cultured in the presence of trametinib (100 nM) or DMSO after lentiviral infection.

2024-02-22 | GSE235183 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data